AnaptysBio 관리

관리 기준 확인 3/4

AnaptysBio CEO는 Dan Faga, Mar2022 에 임명되었습니다 의 임기는 2.67 년입니다. 총 연간 보상은 $ 7.46M, 8.6% 로 구성됩니다. 8.6% 급여 및 91.4% 보너스(회사 주식 및 옵션 포함). 는 $ 9.68M 가치에 해당하는 회사 주식의 1.32% 직접 소유합니다. 9.68M. 경영진과 이사회의 평균 재임 기간은 각각 2.7 년과 3.7 년입니다.

주요 정보

Dan Faga

최고 경영자

US$7.5m

총 보상

CEO 급여 비율	8.6%
CEO 임기	2.7yrs
CEO 소유권	1.3%
경영진 평균 재임 기간	2.7yrs
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Dan Faga 의 보수는 AnaptysBio 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$166m
Jun 30 2024	n/a	n/a	-US$170m
Mar 31 2024	n/a	n/a	-US$163m
Dec 31 2023	US$7m	US$641k	-US$164m
Sep 30 2023	n/a	n/a	-US$148m
Jun 30 2023	n/a	n/a	-US$144m
Mar 31 2023	n/a	n/a	-US$137m
Dec 31 2022	US$25m	US$474k	-US$129m
Sep 30 2022	n/a	n/a	-US$135m
Jun 30 2022	n/a	n/a	-US$108m
Mar 31 2022	n/a	n/a	-US$76m
Dec 31 2021	US$310k	n/a	-US$58m

보상 대 시장: Dan 의 총 보상 ($USD 7.46M )은 UK 시장( $USD 1.45M ).

보상과 수익: Dan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dan Faga (44 yo)

2.7yrs

테뉴어

US$7,461,920

보상

Mr. Daniel R. Faga, also known as Dan, is Director of Affini-T Therapeutics, Inc. from April 2022. He serves as Director at AnaptysBio, Inc. since November 2021 and is its President and Chief Executive Off...

리더십 팀

이름	위치	테뉴어	보상	소유권
Daniel Faga	President	2.7yrs	US$7.46m	1.32% $ 9.7m
Eric Loumeau	Chief Legal Officer	6.3yrs	US$2.26m	0.011% $ 78.1k
Paul Lizzul	Chief Medical Officer	4.3yrs	US$2.44m	0.051% $ 371.1k
Dennis Mulroy	Chief Financial Officer	4.3yrs	US$1.81m	0.016% $ 114.3k
Beth Mueller	Senior Vice President of Human Resources	5.1yrs	데이터 없음	데이터 없음
Martin Dahl	Senior Vice President of Research	2.8yrs	데이터 없음	데이터 없음
Benjamin Stone	Chief Business Officer	less than a year	데이터 없음	데이터 없음
Douglas Rich	Senior Vice President of CMC	1.8yrs	데이터 없음	데이터 없음
Monique Da Silva	Senior Vice President of Corporate Affairs	less than a year	데이터 없음	데이터 없음
Priya Raina	Senior Vice President of Clinical Operations	less than a year	데이터 없음	데이터 없음
Min Bao	Senior Vice President of Clinical Development	less than a year	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: 0HFQ 의 관리팀은 경험 ( 2.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Daniel Faga	President	3yrs	US$7.46m	1.32% $ 9.7m
John Orwin	Independent Chairman of the Board	1.2yrs	US$338.08k	0.011% $ 80.4k
Hollings Renton	Lead Independent Director	9.4yrs	US$342.38k	0.0064% $ 47.0k
John Schmid	Independent Director	9.4yrs	US$335.38k	0.013% $ 94.0k
Dennis Fenton	Independent Director	6.7yrs	US$331.88k	0.0064% $ 47.0k
Magda Marquet	Independent Director	3.8yrs	US$318.38k	0.013% $ 94.0k
Oleg Nodelman	Independent Director	3.6yrs	데이터 없음	데이터 없음
J. Ware	Independent Director	7.3yrs	US$338.38k	0.025% $ 180.8k
Rita Jain	Independent Director	1.6yrs	US$495.60k	0.015% $ 109.3k
Dolca Thomas	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
Luisa Salter-Cid	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
John Monroe	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

3.7yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: 0HFQ 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.

AnaptysBio 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Recent updates

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2024 earnings released: US$1.14 loss per share (vs US$1.41 loss in 3Q 2023)

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

Second quarter 2024 earnings released: US$1.71 loss per share (vs US$1.50 loss in 2Q 2023)

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings released: US$1.64 loss per share (vs US$1.58 loss in 1Q 2023)

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Full year 2023 earnings released: US$6.08 loss per share (vs US$4.57 loss in FY 2022)

No longer forecast to breakeven

No longer forecast to breakeven

High number of new directors

High number of new directors

No longer forecast to breakeven

New minor risk - Profitability

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$1.18 loss in 3Q 2022)

AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

High number of new directors

High number of new directors

AnaptysBio, Inc. Announces Board Changes

High number of new directors

High number of new directors

Second quarter 2023 earnings released: US$1.50 loss per share (vs US$1.15 loss in 2Q 2022)

AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Forecast to breakeven in 2025

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$1.58 loss per share (vs US$1.31 loss in 1Q 2022)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares.

AnaptysBio Announces Portfolio

Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer

Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials

AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

First quarter 2022 earnings released: US$1.31 loss per share (vs US$0.66 loss in 1Q 2021)

AnaptysBio, Inc., Annual General Meeting, Jun 23, 2022

Forecast to breakeven in 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

AnaptysBio, Inc. Announces FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.30 loss in 1Q 2020)

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

Full year 2020 earnings released: US$0.73 loss per share (vs US$3.60 loss in FY 2019)

Revenue beats expectations

AnaptysBio, Inc. Announces Board Changes

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령